Fernando Scazzuso

Fernando Scazzuso

Auto-generated profile, based on publicly available information

Fernando Scazzuso

Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
SRSantiago Rivera
Santiago Rivera
MRMaria de la Paz Ricapito
Maria de la Paz Ricapito
LTLeandro Tomas
Leandro Tomas
JPJosefina Parodi
Josefina Parodi
GMGuillermo Bardera Molina
Guillermo Bardera Molina
FSFernando Scazzuso
Fernando Scazzuso
Background—: Catheter radiofrequency ablation of ventricular arrhythmias (VAs) arising from the left ventricle’s papillary muscles has been associated with inconsistent results. The use of cryoenergy versus radiofrequency has not been compared yet. This study compares outcomes and complications of catheter ablation of VA from the papillary muscles of the left ventricle with either cryoenergy or radiofrequency. Methods and Results—: Twenty-one patients (40±12 years old; 47% males; median ejection fraction 59±7.3%) with drug refractory premature ventricular contractions or ventricular tachycardia underwent catheter cryoablation or radiofrequency ablation. VAs were localized using 3-dimensional mapping, multidetector computed tomography, and intracardiac echocardiography, with arrhythmia foci being mapped at either the anterolateral papillary muscle or posteromedial papillary muscles of the left ventricle. Focal ablation was performed using an 8-mm cryoablation catheter or a 4-mm open-irrigated radiofrequency catheter, via transmitral approach. Acute success rate was 100% for cryoenergy (n=12) and 78% for radiofrequency (n=9; P =0.08). Catheter stability was achieved in all patients (100%) treated with cryoenergy, and only in 2 (25%) patients treated with radiofrequency ( P =0.001). Incidence of multiple VA morphologies was observed in 7 patients treated with radiofrequency (77.7%), whereas none was observed in those treated with cryoenergy ( P =0.001). VA recurrence at 6 months follow-up was 0% for cryoablation and 44% for radiofrequency ( P =0.03). Conclusions—: Cryoablation was associated with higher success rates and lower recurrence rates than radiofrequency catheter ablation, better catheter stability, and lesser incidence of polymorphic arrhythmias.

23 January 2015 in EP Europace
Verified
Journal Article
Closed access
PDF file
RKRoberto Keegan
Roberto Keegan
LALuis Aguinaga
Luis Aguinaga
GFGuilherme Fenelon
Guilherme Fenelon
WUWilliam Uribe
William Uribe
GDGerardo Rodriguez Diez
Gerardo Rodriguez Diez
FSFernando Scazzuso
Fernando Scazzuso
Aims To assess the results of transcatheter ablation of cardiac arrhythmias in Latin America and establish the first Latin American transcatheter ablation registry. Methods and results All ablation procedures performed between 1 January and 31 December 2012 were analysed retrospectively. Data were obtained on the characteristics and resources of participating centres (public or private institution, number of beds, cardiac surgery availability, type of room for the procedures, days per week assigned to electrophysiology procedures, type of fluoroscopy equipment, availability and type of electroanatomical mapping system, intracardiac echo, cryoablation, and number of electrophysiologists) and the results of 17 different ablation substrates: atrio-ventricular node reentrant tachycardia, typical atrial flutter, atypical atrial flutter, left free wall accessory pathway, right free wall accessory pathway, septal accessory pathway, right-sided focal atrial tachycardia, left-sided focal atrial tachycardia, paroxysmal atrial fibrillation, non-paroxysmal atrial fibrillation, atrio-ventricular node, premature ventricular complex, idiopathic ventricular tachycardia, post-myocardial infarction ventricular tachycardia, ventricular tachycardia in chronic chagasic cardiomyopathy, ventricular tachycardia in congenital heart disease, and ventricular tachycardias in other structural heart diseases. Data of 15 099 procedures were received from 120 centres in 13 participating countries (Argentina, Bolivia, Brazil, Chile, Colombia, Cuba, El Salvador, Guatemala, Mexico, Peru, Dominican Republic, Uruguay, and Venezuela). Accessory pathway was the group of arrhythmias most frequently ablated (31%), followed by atrio-ventricular node reentrant tachycardia (29%), typical atrial flutter (14%), and atrial fibrillation (11%). Overall success was 92% with the rate of global complications at 4% and mortality 0.05%. Conclusion Catheter ablation in Latin America can be considered effective and safe.

1 December 2015 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
SRSantiago Rivera
Santiago Rivera
MRMaria de la Paz Ricapito
Maria de la Paz Ricapito
JEJuan Espinoza
Juan Espinoza
DBDiego Belardi
Diego Belardi
GAGaston Albina
Gaston Albina
FSFernando Scazzuso
Fernando Scazzuso

21 December 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RRRoberto Rordorf
Roberto Rordorf
FSFernando Scazzuso
Fernando Scazzuso
KCKyoung Ryul Julian Chun
Kyoung Ryul Julian Chun
SKSurinder Kaur Khelae
Surinder Kaur Khelae
FKFred J. Kueffer
Fred J. Kueffer
TIthe Cryo AF Global Registry Investigators
the Cryo AF Global Registry Investigators
Background: Heart failure (HF) and atrial fibrillation (AF) often coexist; yet, outcomes of ablation in patients with AF and concomitant HF are limited. This analysis assessed outcomes of cryoablation in patients with AF and HF. Methods and Results: The Cryo AF Global Registry is a prospective, multicenter registry of patients with AF who were treated with cryoballoon ablation according to routine practice at 56 sites in 26 countries. Patients with baseline New York Heart Association class I to III (HF cohort) were compared with patients without HF. Freedom from atrial arrhythmia recurrence ≥30 seconds, safety, and health care utilization over 12‐month follow‐up were analyzed. A total of 1303 patients (318 HF) were included. Patients with HF commonly had preserved left ventricular ejection fraction (81.6%), were more often women (45.6% versus 33.6%) with persistent AF (25.8% versus 14.3%), and had a larger left atrial diameter (4.4±0.9 versus 4.0±0.7 cm). Serious procedure‐related complications occurred in 4.1% of patients with HF and 2.6% of patients without HF ( P =0.188). Freedom from atrial arrhythmia recurrence was not different between cohorts with either paroxysmal AF (84.2% [95% CI, 78.6–88.4] versus 86.8% [95% CI, 84.2–89.0]) or persistent AF (69.6% [95% CI, 58.1–78.5] versus 71.8% [95% CI, 63.2–78.7]) ( P =0.319). After ablation, a reduction in AF‐related symptoms and antiarrhythmic drug use was observed in both cohorts (HF and no‐HF), and freedom from repeat ablation was not different between cohorts. Persistent AF and HF predicted a post‐ablation cardiovascular rehospitalization ( P =0.032 and P =0.001, respectively). Conclusions: Cryoablation to treat patients with AF is similarly effective at 12 months in patients with and without HF. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02752737.

1 December 2021 in American Heart Journal
Verified
Journal Article
Open access
NPNikola Pavlovic
Nikola Pavlovic
GCGian-Battista Chierchia
Gian-Battista Chierchia
VVVedran Velagic
Vedran Velagic
JHJean Sylvain Hermida
Jean Sylvain Hermida
SHStewart Healey
Stewart Healey
MKMalte Kuniss
Malte Kuniss
Cryoballoon ablation (CBA) as a first-line rhythm control strategy is superior to antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) recurrence; the impact of first-line CBA on quality of life (QoL) and symptoms has not been well characterized. Patients aged 18 to 75 with symptomatic paroxysmal AF naïve to rhythm control therapy were randomized (1:1) to CBA (Arctic Front Advance, Medtronic) or AAD (Class I or III). Symptoms and QoL were assessed at baseline, 1, 3, 6, 9, and 12 months using the EHRA classification and Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and SF-36v2 questionnaires. Symptomatic palpitations were evaluated via patient diary. Overall, 107 patients were randomized to CBA and 111 to AAD; crossovers occurred in 9%. Larger improvements in the AFEQT summary, subscale and treatment satisfaction scores were observed at 12 months with CBA vs AAD (all P <0.05). At 12 months, the mean adjusted difference in the AFEQT summary score was 9.9 points higher in the CBA group (95% CI: 5.5 -14.2, P <0.001). Clinically important improvements in the SF-36 physical and mental component scores were observed at 12 months in both groups, with no significant between group differences at this timepoint. In the CBA vs AAD group, larger improvements in EHRA class were observed at 6, 9 and 12 months (P <0.05) and the incidence rate of symptomatic palpitations was lower (4.6 vs 15.2 days/year post-blanking; IRR: 0.30, P <0.001). In patients with symptomatic AF, first-line CBA was superior to AAD for improving AF-specific QoL and symptoms. ClinicalTrials.gov number: NCT01803438.

1 October 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
FSFernando A. Scazzuso
Fernando A. Scazzuso
SRSantiago H. Rivera
Santiago H. Rivera
GAGastón Albina
Gastón Albina
MRMaría de la Paz Ricapito
María de la Paz Ricapito
LGLuis Alberto Gómez
Luis Alberto Gómez
AGAlberto Giniger
Alberto Giniger